First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

The US Food and Administration (FDA) has approved the Amplatzer Amulet left atrial appendage occluder (Abbott) to treat people with nonvalvular atrial fibrillation who are at increased risk for stroke ...

A head-to-head, randomized study of the two leading heart implants worldwide for reducing the risk of stroke among people with an irregular pulse found there was little difference between their safety ...

Abbott is recalling the Amplatzer steerable delivery sheath, used to deliver the Amplatzer Amulet left atrial appendage occluder during cardiac catheterization, because of an increased risk of air ...

Boston Scientific and Abbott this week both put forward separate studies supporting their respective implants for sealing off the heart’s left atrial appendage—the pocket within the cardiac muscle ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

BOSTON, MA—For patients with atrial fibrillation who are undergoing left atrial appendage occlusion (LAAO), the Amplatzer Amulet (Abbott) and the first-generation Watchman 2.5 (Boston Scientific) ...

New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in minimizing blood leakage around the valve implant ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) ...